| abstract |
The present invention relates to isolated specific binding members, particularly antibodies or fragments, derivatives or variants therof that recognize and bind amyloid beta 1-42 protein. Methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of amyloid beta protein, including amyloid beta 1-42 are prevalent, in particular Alzheimer's disease, are disclosed. The present invention also relates to pharmaceutical compositions comprising such binding members, antibodies and mimics therof and methods of screening for novel binding members, which may or may not be antibodies. |